Small interfering RNA for the modification of HAMP expression
SiRNAs targeting HAMP mRNA address the inadequacies of current treatments by effectively reducing hepcidin levels, improving iron balance, and treating anemia-related disorders.
Patent Information
- Application Number
- PCT/US2026/026720
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for disorders associated with high hepcidin levels, such as anemia of inflammation (Al) and iron-refractory iron deficiency anemia (IRIDA), are inadequate, as they either fail to effectively reduce hepcidin levels or have adverse reactions, and existing RNA-based therapies do not target iron homeostasis disorders.
Development of small interfering ribonucleic acids (siRNAs) that specifically target hepcidin antimicrobial peptide (HAMP) mRNA, using chemically modified strands to enhance stability and efficacy, thereby reducing hepcidin expression and restoring iron balance.
The siRNAs effectively inhibit HAMP expression, leading to reduced hepcidin levels and improved iron homeostasis, offering therapeutic benefits for conditions like Al and IRIDA, with potential applications in treating anemia and boosting erythropoiesis.
Smart Images

Figure US2026026720_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT SMALL INTERFERING RNA FOR THE MODIFICATION OF HAMP EXPRESSION RELATED APPLICATIONS
[0001] This application claims the benefit of U. S. Provisional Application No.63 / 801,042, filed May 6, 2025, the disclosure of which is incorporated herein by reference in its entirety.SEQUENCE LISTING
[0002] This application contains an electronic Sequence Listing which has been submitted in XML file format with this application, the content of which is incorporated by reference herein in its entirety. The Sequence Listing XML file submitted with this application is entitled “14874-007-228_„SEQ„LISTING.xml”, was created on May 4, 2026, and is 478,053 bytes in size.FIELD
[0003] Provided herein are small interfering ribonucleic acid (siRNA) targeting hepcidin antimicrobial peptide (HAMP) mRNA, and compositions and methods fortheir use, for example, to reduce hepcidin expression, and to treat disorders related to iron homeostasis.BACKGROUND
[0004] iron is important for biological processes such as oxygen transport, DNA synthesis, and cellular respiration. Dysregulation of iron homeostasis leads to various pathological conditions such as anemia, hemochromatosis, and iron overload disorders.
[0005] Hepcidin is a peptide hormone encoded by the HAMP gene that is primarily expressed in the liver where it is produced in hepatocytes. Hepcidin negatively controls intestinal iron absorption in the duodenum, sequesters iron in tissues and lowers serum iron levels. Overexpression of hepcidin is associated with anemia of inflammation (Al), also known as anemia of chronic disease, and iron-refractory iron deficiency anemia (IRIDA).
[0006] Ai occurs in several common disorders, including chronic infections, autoimmune diseases, myelofibrosis, irritable bowel syndrome, chronic kidney disease, anemia of the elderly, advanced cancer, graft versus host disease, congestive heart failure, and chronic obstructive pulmonary disease. Al is one of the most common anemias worldwide and the most frequent anemia in hospitalized patients.
[0007] There remains a need for effective interventions to treat disorders associated with high hepcidin levels. For instance, treatment of Al with oral iron is ineffective since the high hepcidin levels counteract its intestinal absorption. Chronic treatment with red blood cells transfusions is not recommended because of transient effects and adverse reactions; it is limited to severe refractory anemia. Targeted RNA-based therapies, such as small NAI-50120701 S8v2 Page 1 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT interfering RNAs (siRNAs) that downregulate the expression of genes implicated in disease have been approved by the United States Food and Drug Administration targeting, inter alia, hepatic lactate dehydrogenase (nedosiran) and proprotein convertase subtilisin / kexin type-9 (PCSK9) (inclisiran), none, however, address disorders related to iron homeostasis.
[0008] Silencing HAMP mRNAwith siRNA offers a promising strategy to regulate hepcidin levels and restore iron balance in individuals with disorders linked to elevated hepcidin, such as Ai and IRIDA.SUMMARY
[0009] in one aspect, provided herein is a small interfering ribonucleic acid (siRNA) for inhibiting expression of hepcidin antimicrobial peptide (HAMP), wherein the siRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand and antisense are a duplex selected from the group consisting of duplexes listed in TABLE 4.
[0010] in some embodiments, provided herein is a siRNA comprising a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a modified nucleotide sequence selected from the group consisting of:5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648),5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649), 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650),5'-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651),5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732),5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733),5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734),5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735), 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836),5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837),5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838), and 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839);wherein “a” is 2’-O-methyladenosine-3’-phosphate, “as” is 2’-O-methyladenosine-3’-phosophorothioate, “Af” is 2’-fluoroadenosine-3’-phosphate, “Afs” is 2’-fluoroadenosine-3’-phosphorothioate, “c” is 2’-O-methylcytidine-3’-phosphate, “cs is 2’-O-methylcytidine-3’-phosphorothioate, “Cf” is 2’-fluorocytidine-3’-phosphate, “Cfs” is 2’-fluorocytidine-3’-phosphorothioate, “g” is 2’-0-methylguanosine-3’-phosphate, “gs” is 2’-0-methylguanosine-3’-phosphorothioate, “Gf” is 2’-fluoroguanosine-3’-phosphate, “u” is 2’-0-methyluridine-3’-phosphate, “us” is 2’-0-methyluridine-3’-phosphorothioate, “Uf” is 2’-fluorouridine-3’-phosphate, and “Ufs” is 2’-fluorouridine-3’-phosphorothioate.NAI-50120701 S8v2 Page 2 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0011] In some embodiments, the antisense strand comprises a5’-vinylphosphonate at the 5’ end.
[0012] In some embodiments, the siRNA further comprises a sense strand comprises a modified nucleotide sequence selected from the group consisting of:5’-asascagaCfgGfGfAfcaacUfUfgcaa-3’ (SEQ ID NO:354),5'-asascagaCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355),5’-asascagaCfgGfGfAfcaacuugcaa-3’ (SEQ ID NO:356),5’-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357),5’-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358),5’-asascaGfaCfGfGfgacaAfcuUfga-3’ (SEQ ID NO:359),5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480),5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’(SEQ ID NO:481),5’-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482),5’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483),5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484),5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485),5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636),5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637),5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638),5’-usgsucauCfgAfUfCfaaagUfGfugga-3’(SEQ ID NO:639),5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NO:640), and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 );wherein “a” is 2’-O-methyladenosine-3’-phosphate, “as” is 2’-O-methyladenosine-3’-phosophorothioate, “Af” is 2’-fluoroadenosine-3’-phosphate, “c” is 2’-O-methylcytidine-3’-phosphate, “cs is 2’-O-methylcytidine-3’-phosphorothioate, “Cf” is 2’- fluorocytidine-3’-phosphate, “g” is 2’-O-methylguanosine-3’-phosphate, “gs” is 2’-O-methylguanosine-3’-phosphorothioate, “Gf” is 2’-fluoroguanosine-3’-phosphate, “u” is 2’-O-methyluridine-3’-phosphate, “us” is 2’-O-methyluridine-3’-phosphorothioate, and “Uf” is 2’-fluorouridine-3’-phosphate, and “Ufs” is 2’-fluorouridine-3’-phosphorothioate.
[0013] In certain embodiments, the 3’ end of the sense strand is covalently attached to a triantennary GalNAc. In certain embodiments, the triantennary GalNAc is L96, wherein the L96 isNAI-50120701 S8v2 Page 3 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0014] in certain embodiments, the antisense strand and sense strand of the siRNA comprise a pair of modified nucleotides sequences selected from the group consisting of:(a) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and 5’-asascagaCfgGfGfAfcaacUfUfgcaa-3’ (SEQ ID NO:354);(b) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and 5’-asascagaCfgGfGfAfcaacUfUfgcaa-3’ (SEQ ID NO:354);(c) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and 5’-asascagaCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355);(d) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and 5’-asascagaCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355);(e) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and 5’-asascagaCfgGfGfAfcaacuugcaa-3’ (SEQ ID NO:356);(f) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and 5’-asascagaCfgGfGfAfcaacuugcaa-3’ (SEQ ID NO:356);(g) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650) and5’-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357);(h) 5’-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) and 5’-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357);(i) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650) and5’-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358);(j) 5’-usCfsaagUfuGf UfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) and 5’-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358);(k) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650) and5’-asascaGfaCfGfGfgacaAfcullfga-3’ (SEQ ID NO:359);(l) 5’-usCfsaagUfuGf UfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) and 5’-asascaGfaCfGfGfgacaAfcuUfga-3’ (SEQ ID NO:359);(m) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) andNAI-50120701 S8v2 Page 4 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT 5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480);(n) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and 5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480);(o) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) and5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’(SEQ ID NO:481);(p) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and 5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’ (SEQ ID NO:481);(q) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) and5’-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482);(r) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and 5’-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482);(s) 5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) and 5’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483);(t) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and 5’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483);(u) 5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) and 5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484);(v) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and 5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484);(w) 5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) and 5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485);(x) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and 5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485);(y) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(z) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(aa) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfiicaaAfguGfua-3’ (SEQ ID NO:637);(bb) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(cc) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(dd) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(ee) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);NAI-50120701 S8v2 Page 5 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT (ff) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(gg) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NO:640);(hh) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NO:640);(ii) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ); and(jj) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ).
[0015] In some embodiments, the antisense strand and sense strand comprise a pair of modified nucleotides sequences selected from the group consisting of:(y) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(z) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(aa) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(bb) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(cc) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(dd) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(ee) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(ff) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(gg) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NO:640);(hh) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NO:640);(ii) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ); and(jj) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ).NAI-50120701 S8v2 Page 6 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0016] In certain embodiments, the antisense strand and sense strand comprise:5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638).
[0017] In some embodiments, the siRNA the antisense strand and sense strand comprise:5'-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and 5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480).
[0018] In some embodiments, a siRNA as described herein contains an antisense strand comprising 5’-(E)-vinylphosphonate-2’-O-methyluridine (“vinu”) at its 5’ end and a sense strand covalently attached to L96 at its 3’ end.
[0019] In one aspect, provided herein is a cell comprising a siRNA as described herein.
[0020] In one aspect, provided herein is a pharmaceutical composition comprising a siRNA as described herein and a pharmaceutically acceptable excipient or carrier.
[0021] In some embodiments the pharmaceutical composition further comprises a lipid nanoparticle formulation.
[0022] in one aspect, provided herein is a method of inhibiting HAMP expression in a cell, the method comprising: (a) introducing a siRNA as described herein into the cell, and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of HAMP mRNA, thereby inhibiting expression of HAMP in the cell.
[0023] In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of a siRNA as described herein. In one aspect, provided herein is a siRNA for use in reducing hepcidin serum concentration comprising administering to a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used forthe manufacture of a medicament for reducing hepcidin serum concentration.
[0024] In one aspect, provided herein is a method of treating a disease, condition or disorder associated with elevated serum hepcidin, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a siRNA as described herein. In one aspect, provided herein is a siRNA for use in treating a disease, condition or disorder associated with elevated serum hepcidin comprising administering to a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used for the manufacture of a medicament for treatment of a disease, condition or disorder associated with elevated serum hepcidin. in some embodiments, the disease, condition or disorder associated with elevated serum hepcidin is (i) an anemia associated with elevated hepcidin; (ii) an ironNAI-50120701 S8v2 Page 7 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”).
[0025] In one aspect, provided herein is a method of boosting erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of a siRNA as described herein, in one aspect, provided herein is a siRNA for use in boosting erythropoiesis comprising administering to a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used for the manufacture of a medicament for boosting erythropoiesis.
[0026] In one aspect, provided herein is a method of treating (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”) in a subject in need thereof, the method comprising administerin to the subject a therapeutically effective amount of a siRNA as described herein. In one aspect, provided herein is a siRNA for use in treating (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”) comprising administering to a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used for the manufacture of a medicament for treatment of (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”).
[0027] In some embodiments provided herein is a method of treating an anemia of inflammation (“Al”) comprising administeringto a subject having Al a therapeutically effective amount of a siRNA as described herein. In one embodiment, provided herein is a siRNA for use in treating an anemia of inflammation (“Al”) comprising administerin to a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used for the manufacture of a medicament for treatment of an anemia of inflammation (“Al”). In certain embodiments, the subject with Al has a chronic infection, an autoimmune disease, chronic kidney disease, an anemia of the elderly, an advanced cancer, graft versus host disease, congestive heart failure, myelofibrosis, a myelodysplastic syndrome (MDS), irritable bowel syndrome, rheumatoid arthritis, sepsis, or chronic obstructive pulmonary disease.
[0028] In some embodiments of a method of treating a disease, condition or disorder associated with elevated serum hepcidin, the method further comprises administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease, disorder or condition. In one embodiment, provided herein is a siRNA for use in treating a disease, condition or disorder associated with elevated serumNAI-50120701 S8v2 Page 8 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT hepcidin comprising administering to a subject in need thereof a therapeutically effective amount of a siRNA as described herein and a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease, disorder or condition.BRIEF DESCRIPTION OF THE FIGURES
[0029] FIG. 1 is a scatter plot showing the relative reduction (% knockdown) in BMP6-stimulated HAMP mRNA production in Hep3B cells exhibited by 0.1 nM and 10 nM concentrations of exemplary siRNAs as described herein. siRNAs indicated as “selected” achieved >85% knockdown of hepcidin at 10 nM concentration.
[0030] FIG.2 depicts dose-response curves representing the reduction in BMP6-stimulated HAMP mRNA production (% HAMP knockdown) in Hep3B cells versus the concentration of 12 exemplary siRNAs.
[0031] FIG.3 depicts dose-response curves for the reduction in BMP6-stimulated HAMP mRNA production (% knockdown) and percent inhibition of hepcidin expression in Hep3B cells for BD-80738 and BD-80742.
[0032] FIG.4 depicts dose-response curves from five independent replicates (n1 to n5) for HAMP knockdown in primary human hepatocytes (PPH) via free uptake ofBD-80738,
[0033] FIG.5 depicts dose-response curves showing percent inhibition of HAMP expression in BMP6-stimulated Hep3B cells as a function of siRNA concentration for BD-80738 and a reference HAMP-targeting siRNA (AD-45723).
[0034] FIG.6 depicts dose-response curves showing percent inhibition of HAMP mRNA expression and hepcidin levels in primary human hepatocytes via free uptake of BD-80738 and reference AD-45723.
[0035] FIG.7 depicts plasma stability profiles of BD-80738 and AD-45723, showing the remaining percentage of siRNA antisense (AS) strand over time following incubation in human plasma.
[0036] FIG.8 depicts dose-dependent knockdown of HAMP mRNA in primary cynomolgus hepatocytes by BD-80738 across three independent replicates (n1 to n3).DETAILED DESCRIPTION
[0037] In one aspect, provided herein is a short interfering ribonucleic acid (siRNA) capable of specifically binding and silencing hepcidin antimicrobial peptide (HAMP) mRNA. The siRNA includes chemically modified nucleotides to enhance stability, reduce immunogenicity, and improve efficacy. In some embodiments, the siRNA effects the RNA-induced silencing complex (RlSC)-mediated cleavage of RNA transcripts of the HAMP gene.NAI-50120701 S8v2 Page 9 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0038] In one aspect, provided herein are cells and pharmaceutical compositions comprisingthe siRNA and methods for using the siRNA for inhibiting HAMP expression in a cell or a subject where the siRNA targets HAMP.
[0039] In one aspect, provided herein are methods of using the siRNA for reducing hepcidin serum concentration in subject and / or for treating a disease, condition or disorder, or symptom or complication thereof, associated with an elevated hepcidin level, such as, for example, an iron refractory iron deficiency anemia, a hepcidin-producing adenoma, or an anemia of inflammation (“Al”).Terminology
[0040] The term “linker” as used herein means an organic moiety that connects by way of covalent bonds two parts of a compound, e.g., a strand of a siRNA to an asialoglycoprotein receptor (ASGPR) ligand. Linkers can comprise, for example, a direct bond or an atom such as oxygen or sulfur, or a unit such as NR’, CH2, CHC(O), C(O)NH, S(O), SO2, SO2NH, or a chain of atoms, such as, but not limited to, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, any of which may be substituted or unsubstituted and in which one or more methylene can be interrupted or terminated by O, C(O), C(O)NH, S, S(O), SO2, NR’, C(O), or substituted or unsubstituted heterocyclic; where R’ is hydrogen, acyl, or alkyl. In certain embodiments, the linker is between about 1 to 24 atoms, 4 to 20 atoms, or 8 to 16 atoms.
[0041] The terms “treat,” “treating,” and “treatment” as used herein mean to relieve or alleviate one or more symptoms associated with a disease, condition or disorder; or to delay or prevent the worsening or progression of the disease, condition or disorder or symptom thereof; or to reduce severity of a disease, condition or disorder or symptom thereof.NAI-50120701 S8v2 Page 10 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0042] As used herein, the phrase “effective amount” refers to an amount of each active agent (e.g., siRNA) that will elicit a biological or medical response of a tissue, system or subject that is being sought by a researcher, veterinarian, medical doctor or other clinician. In some embodiments, the therapeutic effect is reduced hepcidin level or activity, increased level of serum iron and / or transferrin saturation (TSAT %), increased erythropoiesis, decreased level of circulating transferrin level, and / or alleviated disease conditions (e.g., reduced anemia).
[0043] The term “subject” as used herein refers to a mammal, including but not limited to, human, non-human primate, cow, sheep, goat, horse, dog, cat, rabbit, rat. In some embodiments, the subject is a patient, e.g., a human patient that has or is suspected of having a disease or a condition associated with, or may give rise to, a functional iron deficiency (e.g., anemia).
[0044] “G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or“nucleotide” can also referto a modified nucleotide, as further detailed below, or a surrogate replacement moiety (see, e.g., Table 1). The skilled person understands that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of siRNA provided herein by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively, to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods provided in the disclosure.
[0045] Table 1 explains abbreviations of nucleotide monomers used in nucleic acid sequences herein. It will be understood that, unless otherwise indicated, these monomers, when present in an oligonucleotide, are mutually linked by 5’-3’-phosphodiester bonds.TABLE 1NAI-50120701 S8v2 Page 11 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT TABLE 1
[0046] Without intending to be limited to any embodiment or mechanism, it is believed that when a siRNA enters a cell, it is incorporated into the RNA-induced silencing complex (RISC), which includes the core protein Argonaute (AGO). Subsequently, the siRNA is unwound into single-stranded RNAs and the antisense strand remains associated with AGO to form an active RISC, whereas the sense strand is degraded. The antisense strand forms base-pairings with a target transcript (mRNA), and AGO cleaves the target to silence its function (gene expression).
[0047] In one aspect, provided herein are siRNAs designed to specifically target a region of HAMP mRNA that is conserved among different species or that is critical to the gene’s expression. A siRNA as provided herein can, for example, bind to HAMP mRNA in a cell and thereby result cleavage and degradation of the mRNA, leadin to reduced hepcidin expression.
[0048] In some embodiments, the siRNA is 19-25 nucleotides in length and consists of a sense strand and an antisense strand, where the antisense strand is complementary to NAI-50120701 S8v2 Page 12 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT a region of the HAMP mRNA. The sense and antisense strands are typically duplexed, but in some embodiments may be present as single-stranded RNA molecules capable of inducing RNA interference.
[0049] As described in the Examples below, Table 2 shows 49 unique siRNA duplexes in 19 / 21 mer format and 49 unique siRNA duplexes in 21 Z23mer format, totaling 98 siRNA duplexes, targeting the HAMP gene. From this set of siRNA duplexes, new set of 98 unique siRNA duplexes targeting the HAMP gene, wherein siRNA antisense strand position 1 (AS1 ) is “U,” and the corresponding siRNA sense strand position 19 (SS19) is “A” were developed, which are shown in Table 3. Thermodynamically preferred A / U base pairing at the 5’-end of the antisense strand is advantageous for strand orientation during RISC loading. While these siRNAs are promising therapeutic agents for regulating the expression of HAMP, these molecules can be vulnerable to nuclease digestion in vivo, which would impair their clinical applications. Modifications, such as introducing unnatural nucleotide(s) and / or antinucleoside linkages into a siRNA can enhance stability and / or resistance to nuclease digestion and / or reduce off-target effects when compared to an unmodified siRNA counterpart. However, the types and positions of modifications made to a “parent” unmodified siRNA can impact the gene silencing activity of the resultant modified siRNA.
[0050] Accordingly, provided herein in certain embodiments are specific modification patterns, that is, a combination of nucleotide modifications and phosphorothioate (“s”) bonds at defined positions in the sense and the antisense strands of a siRNA. In certain embodiments, the modifications provide modified siRNAs having increased potency, less cytotoxicity and / or greater stability in vivo.
[0051] In some embodiments, provided herein is a siRNA comprising a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand is selected from the group of antisense strands listed in Table 4 (SEQ ID NOs:648 to 843).
[0052] In some embodiments, the siRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand and antisense are a duplex selected from the group consisting of the duplexes listed in Table 4.
[0053] In the nucleotide sequences in Table 4,a, c, g, and u are 2’-O-methyladenosine-3’-phosphate, 2’-O-methylcytidine- 3’-phosphate, 2’-O-methylguanosine-3’-phosphate, and 2’-O-methyluridine-3’-phosphate, respectively;as, cs, gs, and us are 2’-0-methyladenosine-3’-phosophorothioate, 2’-O-methylcytidine-3’-phosphorothioate, 2’-O-methylguanosine-3’-phosphorothioate, and 2’-0-methyluridine-3’-phosphorothioate, respectively;Af, Cf, Gf, and Uf are 2’-fluoroadenosine-3’-phosphate, 2’-fluorocytidine-3’-NAI-50120701 S8v2 Page 13 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT phosphate, 2’-fluoroguanosine-3’-phosphate, and 2’-fluorouridine-3’-phosphate, respectively; andAfs, Cfs, Gfs, and Ufs are 2’-fluoroadenosine-3’-phosphorothioate, 2’-fluorocytidine-3’-phosphorothioate, 2’-fluoroguanosine-3’-phosphorothioate, and 2’-fluorouridine-3’-phosphorothioate, respectively.
[0054] In some embodiments, the antisense strand of a siRNA as provided herein (e.g., any one of SEQ ID NOs:648 to 843 in Table 4) has a phosphorylated 5’ end and a hydroxylated 3' end.
[0055] In some embodiments, the antisense strand of a siRNA as provided herein (e.g., any one of SEQ ID NOs:648 to 843 in Table 4) comprises a 5’-phosphate, a 5’-alkyl-phosphonate, a 5’-alkylene phosphonate, or a 5’-alkenyl-phosphonate. In some embodiments, the antisense strand comprises a 5’-vinyl-phosphonate. In some embodiments, the antisense strand comprises a 5’-(E)-vinyl-phosphonate.
[0056] in some embodiments, the antisense strand of a siRNA as provided herein (e.g., any one of SEQ ID NOs:648 to 843 in Table 4) has 5’-(E)-vinylphosphonate-2’-O-methyluridine at its 5’ end.
[0057] In some embodiments, the sense strand of a siRNA as provided herein (e.g., any one of SEQ ID NOs:354 to 647 in Table 4) has a phosphorylated 5' end and a hydroxylated 3' end.
[0058] In some embodiments of a siRNA as provided herein, an asialoglycoprotein receptor (ASGPR) ligand is covalently attached, directly or indirectly through a linker, to the sense strand (e.g., any one of SEQ ID NOs:354 to 647 in Table 4). In certain embodiments, the ASGPR ligand comprises N-acetylgalactosamine (GalNAc).
[0059] In some embodiments, the sense strand of a siRNA as provided herein (e.g., any one of SEQ ID NOs:354 to 647 in Table 4) comprises a GalNAc covalently attached, directly or indirectly through a linker, to the 3’ end of the sense strand. In some embodiments, the sense strand of a siRNA as provided herein (e.g., any one of SEQ ID NOs:354 to 647 in Table 4) comprises a biantennary GalNAc covalently attached directly or indirectly through a linker, to the 3’ end of the sense strand. In some embodiments, the sense strand of a siRNA as provided herein (e.g., any one of SEQ ID NOs:354 to 647 in Table 4) comprises a triantennary GalNAc covalently attached directly or indirectly through a linker, to the 3’ end of the sense strand.
[0060] GalNAc-siRNA conjugates, including the linkers by which one or more GalNAc moieties are covalently attached to a siRNA strand, are well known in the art, see, e.g., US 2024 / 0327842A1, US 2024 / 0417422A1, and US Pat. Nos. 8,106,022B2, 8,877,91762, 9,228, 188B2, and 10,808,24662, the contents of which are incorporated herein by reference in their entireties.NAI-50120701 S8v2 Page 14 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0061] In some embodiments, a strand of a siRNA as provided herein comprises an ASGPR ligand wherein the ASGPR ligand is
[0062] In some embodiments, the 3’-end of the sense strand of a siRNA as provided herein (e.g., any one of SEQ ID NOs:354 to 647 in Table 4) is covalently attached to L96, wherein L96 is
[0063] In some embodiments of a siRNA as provided herein, the antisense strand comprises 5’-(E)-vinylphosphonate-2’-O-methyluridine (“vinu”) at its 5’ end and the sense strand is covalently attached to L96 at its 3’ end.
[0064] In some embodiments, the siRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a modified nucleotide sequence selected from the group consisting of:5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648),5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649),NAI-5012070188v2 Page 15 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650),5’-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ),5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732),5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733),5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734),5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735),5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836),5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837),5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838), and5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839);wherein “a” is 2’-O-methyladenosine-3’-phosphate, “as” is 2’-O-methyladenosine-3’-phosophorothioate, “Af” is 2’-fluoroadenosine-3’-phosphate, “Afs” is 2’-fluoroadenosine-3’-phosphorothioate, “c” is 2’-O-methylcytidine-3’-phosphate, “cs is 2’-O-methylcytidine-3’-phosphorothioate, “Cf” is 2’-fluorocytidine-3’-phosphate, “Cfs” is 2’-fluorocytidine-3’-phosphorothioate, “g” is 2’-O-methylguanosine-3’-phosphate, “gs” is 2’-O-methylguanosine-3’-phosphorothioate, “Gf” is 2’-fluoroguanosine-3’-phosphate, “u” is 2’-O-methyluridine-3’-phosphate, “us” is 2’-O-methyluridine-3’-phosphorothioate, “Uf” is 2’-fluorouridine-3’-phosphate, and “Ufs” is 2’-fluorouridine-3’-phosphorothioate.
[0065] In some embodiments, the antisense strand comprises a 5’-phosphate, a 5’-alkyl-phosphonate, a 5’-alkylene phosphonate, or a 5’-alkenyl-phosphonate. In some embodiments, the antisense strand comprises a 5’-vinyl-phosphonate. In some embodiments, the antisense strand comprises a 5’-(E)-vinyl-phosphonate. In some embodiments, the 5’ end of the antisense comprises 5’-(E)-vinylphosphonate-2’-O-methyluridine.
[0066] In some embodiments, the siRNA further comprises a sense strand comprising a modified nucleotide sequence selected from the group consisting of:5’-asascagaCfgGfGfAfcaacUfUfgcaa-3’(SEQ ID NO:354),5’-asascagaCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355),5’-asascagaCfgGfGfAfcaacuugcaa-3’ (SEQ ID NO:356), 5’-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357), 5’-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358),5’-asascaGfaCfGfGfgacaAfcuUfga-3’ (SEQ ID NO:359), 5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480), 5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’ (SEQ ID NO:481),5’-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482), S’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483), 5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484),5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485),5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636), 5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637), 5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638),NAI-50120701 S8v2 Page 16 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT 5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639),5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NQ:640), and5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641);wherein “a” is 2’-Q-methyladenosine-3’-phosphate, “as” is 2’-O-methyladenosine-3’-phosophorothioate, “Af” is 2’-fluoroadenosine-3’-phosphate, “Afs” is 2’-fluoroadenosine-3’-phosphorothioate, “c” is 2’-O-methylcytidine-3’-phosphate, “cs is 2’-O-methylcytidine-3’-phosphorothioate, “Cf” is 2’-fluorocytidine-3’-phosphate, “Cfs” is 2’-fluorocytidine-3’-phosphorothioate, “g” is 2’-O-methylguanosine-3’-phosphate, “gs” is 2’-O-methylguanosine-3’-phosphorothioate, “Gf” is 2’-fluoroguanosine-3’-phosphate, “u” is 2’-O-methyluridine-3’-phosphate, “us” is 2’-O-methyluridine-3’-phosphorothioate, “Uf” is 2’-fluorouridine-3’-phosphate, and “Ufs” is 2’-fluorouridine-3’-phosphorothioate.
[0067] In some embodiments, an ASGPR ligand is covalently attached to the sense strand. In certain embodiments, a biantennary GalNAc or triantennary GalNAc is covalently attached to the sense strand, in certain embodiments, the 3’ end of the sense strand is covalently attached to a triantennary GalNAc. In certain embodiments, the triantennary GalNAc is L96.
[0068] In some embodiments, the antisense strand and sense strand comprise a pair of modified nucleotides sequences selected from the group consisting of:(a) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and 5’-asascagaCfgGfGfAfcaacUfUfgcaa-3’ (SEQ ID NO:354);(b) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and 5’-asascagaCfgGfGfAfcaacUfUfgcaa-3’ (SEQ ID NO:354);(c) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and 5’-asascagaCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355);(d) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and 5’-asascagaCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355);(e) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and 5’-asascagaCfgGfGfAfcaacuugcaa-3’ (SEQ ID NO:356);(f) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and 5’-asascagaCfgGfGfAfcaacuugcaa-3’ (SEQ ID NO:356);(g) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NQ:650) and5’-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357);(h) 5’-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) and 5’-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357);(i) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NQ:650) and5’-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358);(j) 5’-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) andNAI-50120701 S8v2 Page 17 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT 5’-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358);(k) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650) and5’-asascaGfaCfGfGfgacaAfcuUfga-3’ (SEQ ID NO:359);(l) 5’-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) and 5’-asascaGfaCfGfGfgacaAfcullfga-3’ (SEQ ID NO:359);(m) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) and5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480);(n) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and 5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480);(o) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) and5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’ (SEQ ID NO:481);(p) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and 5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’ (SEQ ID NO:481);(q) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) and5’-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482);(r) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and 5’-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482);(s) 5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) and 5’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483);(t) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and 5’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483);(u) 5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) and 5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484);(v) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and 5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484);(w) 5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) and 5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485);(x) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and 5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485);(y) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(z) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(aa) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(bb) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);NAI-50120701 S8v2 Page 18 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT (cc) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(dd) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(ee) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagUfGfugga-3' (SEQ ID NO:639);(ff) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(gg) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NQ:640);(hh) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NQ:640);(ii) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ); and(jj) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ).
[0069] In some embodiments, the antisense strand and sense strand comprise a pair of modified nucleotides sequences selected from the group consisting of:(y) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(z) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(aa) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(bb) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(cc) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(dd) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(ee) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(ff) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(gg) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NQ:640);(hh) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) andNAI-50120701 S8v2 Page 19 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT 5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NO:640);(ii) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ); and(jj) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ).
[0070] In some embodiments, the antisense strand and sense strand comprise:5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and 5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638).
[0071] In some embodiments, the antisense strand and sense strand comprise:5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and 5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480).
[0072] In some embodiments of a siRNA as described herein, an ASGPR ligand is covalently attached to the 3’ end of the sense strand and a 5’-phosphate, a 5’-alkyl-phosphonate, a 5’-alkylene phosphonate, or a 5’-alkenyl-phosphonate is covalently attached to the 5’ end of the antisense strand.
[0073] In some embodiments, the ASGPR ligand is a triantennary GalNAc. In certain embodiments, the triantennary GalNAc is L96.
[0074] In some embodiments, the 5’ end of the antisense comprises 5’-(E)-vinylphosphonate-2’-0-methyluridine.
[0075] In one aspect provided herein is a cell comprising a siRNA as described above. In certain embodiments, the cell is a cultured cell. The cultured cell can, for example, be in cell culture or in a tissue culture. In some embodiments, the cell is a primary cell culture. In some embodiments, the cell is a hepatocyte.
[0076] In one aspect, provided herein is a pharmaceutical composition comprising the siRNA as described herein and a pharmaceutically acceptable excipient or carrier.
[0077] It will be understood that pharmaceutical compositions as provided herein are formulated based on the mode of delivery. In some embodiments, the pharmaceutical composition is formulated for intravenous (IV), subcutaneous (SC), or intramuscular (IM) administration. In some embodiments, the pharmaceutical composition is formulated for transdermal, oral, parenteral, infusion, subdermal, intraperitoneal, intraparenchymal, intrathecal, or intraventricular administration.
[0078] A “pharmaceutically acceptable excipient” refers to a broad range of ingredients that may be combined with a siRNA as described herein to prepare the pharmaceutical composition. An excipient can include, but is not limited to, one or more of the following of a diluent, buffer, colorant, vehicle (including a delivery vehicle), cryoprotectant, surfactant, tonicity-adjusting agent, anti-adherent, glidant, disintegrant,NAI-50120701 S8v2 Page 20 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT binder, lubricant, sorbent, preservative, and the like. The choice and concentration of excipients may vary depending on the intended route of administration
[0079] Pharmaceutically acceptable delivery vehicles for delivering siRNAs are known in art, see, e.g., Kalina Paunovska, et al., Nature Reviews Genetics, vol. 23, pages 265-280 (2022), and Hyun Jin Kim et al., Advanced Drug Delivery Reviews, vol. 104, pages 61-77 (2016), the contents of which are incorporated herein by reference in their entireties.
[0080] In some embodiments, the pharmaceutical composition comprises liposomes, lipid nanoparticles, polymeric nanoparticles, or other suitable delivery vehicles to facilitate the efficient delivery of a siRNA as described herein to a target tissue (e.g., liver) or cells (e.g., hepatocytes). In some embodiments of the pharmaceutical composition provided herein, the pharmaceutical composition comprises a lipid nanoparticle (LNP) formulation.
[0081] In some embodiments, the pharmaceutical composition comprises a siRNA as described herein partially or fully encapsulated within a lipid nanoparticle (LNP). The LNP may include one or more ionizable cationic lipids, which become protonated at acidic pH to facilitate endosomal escape. Additional components of the LNP may include a phospholipid (e.g., DSPC), cholesterol, and a polyethylene glycol (PEG)-lipid. The PEG-lipid may be included to enhance particle stability and circulation time and may be designed to shed upon administration to permit cellular uptake.
[0082] Methods for producing stable polynucleotide delivery vehicles that incorporate a polynucleotide / cationic lipid complex as structural components of the delivery vehicle are described in, e.g., PCT Publication No. WO 96 / 37104, the content of which is incorporated herein by reference in its entirety.
[0083] In some embodiments the siRNA can, for example, be fully encapsulated in a lipid formulation, such as, an LNP or other polynucleotide / lipid particles. An LNP can, for example, contain an ionizable amino lipid (cationic lipid), a phosphatidylcholine, a steroid (cholesterol), and a coat lipid (e.g., a PEG-lipid conjugate), see, e.g., Yuen Yi C. Tam, et al., Pharmaceutics, vol. 5, pages 498-507 (2013), the content of which is incorporated herein by reference in its entirety. Polynucleotide-lipid particles and their method of preparation are disclosed in, e.g., U. S. Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410;6,815,432; 9,228,188 and PCT Publication No.96 / 40964.
[0084] In some embodiments, the LNP formulation is characterized by a particle diameter between 60 and 100 nm, a near-neutral surface charge at physiological pH, and encapsulation efficiency of at least 70% with respect to the siRNA payload. In certain embodiments, the LNP is surface-functionalized with a hepatocyte-targeting ligand, such as GalNAc or an antibody or peptide that binds a hepatocyte-specific receptor.NAI-50120701 S8v2 Page 21 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0085] In some embodiments, the pharmaceutical composition comprises a polymeric nanoparticle in which the siRNA is complexed with a biodegradable polymer. Suitable polymers include, but are not limited to, poly(lactic-co-glycolic acid) (PLGA), polyethyleneimine (PEI), poly(beta-amino ester)s, or chitosan. The polymeric carrier may optionally be conjugated to a hepatocyte-targeting moiety or modified with functional groups to enhance siRNA binding, release, or biocompatibility.
[0086] In some embodiments, the pharmaceutical composition includes an inorganic nanoparticle carrier. Examples of suitable inorganic materials include gold, silica, or iron oxide nanoparticles. These nanoparticles may be surface-functionalized with siRNA via covalent or electrostatic interactions, and further conjugated to hepatocyte¬ targeting ligands.
[0087] Hybrid delivery systems are also contemplated. In such systems, a siRNA molecule is delivered via a composition that combines features of two or more of the aforementioned delivery systems. For example, a siRNA may be both encapsulated in a lipid nanoparticle and conjugated to a GalNAc ligand, thereby benefiting from both passive liver targeting and receptor-mediated uptake.
[0088] The pharmaceutical composition may be formulated as an aqueous solution, suspension, or as lyophilized powder for reconstitution. In some embodiments, the pharmaceutical composition is sterile, pyrogen-free, isotonic, and pH-adjusted for physiological compatibility. The final formulation may be provided in a single-use vial, prefilled syringe, or other suitable dosage form suitable for the desired type of administration such as, e.g., any of those described above.
[0089] Manufacturing methods for a pharmaceutical composition disclosed herein may include techniques such as microfluidic mixing, solvent injection, emulsification, or electrospray, depending on the nature of the carrier system. Suitable purification methods include filtration, dialysis, or chromatography to remove unencapsulated siRNA, unreacted ligands, or residual solvents.
[0090] In one aspect, provided herein is a method of inhibiting HAMP expression in a cell, the method comprising: (a) introducing the siRNA provided herein into the cell and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of HAMP mRNA, thereby inhibiting expression of HAMP in the cell.
[0091] In some embodiments, the cell is in vitro, e.g., in a cell culture. In some embodiments the cell is in tissue culture. In some embodiments the cell is in a mammal.
[0092] The phrase “inhibiting HAMP expression” as used herein refers to the at least partial suppression of the HAMP gene. In some embodiments, HAMP expression is reduced by at least 30%. In some embodiments, the HAMP expression is reduced by at least 50%. In some embodiments, the HAMP expression is reduced by at least 75%. InNAI-50120701 S8v2 Page 22 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT some embodiments, the HAMP expression is reduced by at least 80%. In some embodiments, the HAMP expression is reduced by at least 95%. Methods for quantifying HAMP expression in a cell are known in the art, which include, for instance, measuring HAMP mRNA levels (e.g., quantitative PCR, RNA sequencing, northern blotting) or measuring hepcidin protein levels (e.g., western blotting, enzyme-linked immunosorbent assay). In certain embodiments, the degree of inhibition of the HAMP gene is in terms of a functional linked parameter such as, for instance, secreted hepcidin level, or, for instance, hepcidin serum concentration.
[0093] The siRNAs and pharmaceutical compositions of the present disclosure can be used to treat diseases and conditions associated with abnormal iron metabolism. These include, but are not limited to, iron deficiency anemia and other disorders where the dysregulation of HFE2 or hepcidin contributes to the pathogenesis of the condition.
[0094] In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of a siRNA as described herein. In one aspect, provided herein is a siRNA for use in reducing hepcidin serum concentration comprising administerin to a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used forthe manufacture of a medicament for reducing hepcidin serum concentration.
[0095] In one aspect, provided herein is a method of boosting erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of a siRNA as described herein. In one aspect, provided herein is a siRNA for use in boosting erythropoiesis comprising administering to a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used forthe manufacture of a medicament for boosting erythropoiesis.
[0096] In one aspect, provided herein is a method of treating a disease, condition or disorder associated with elevated serum hepcidin, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a siRNA as described herein. In one aspect, provided herein is a siRNA for use in treating a disease, condition or disorder associated with elevated serum hepcidin comprising administeringto a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used for the manufacture of a medicament for treating a disease, condition or disorder associated with elevated serum hepcidin.
[0097] In some embodiments, the disease, condition or disorder associated with elevated serum hepcidin is (i) an anemia associated with elevated hepcidin; (ii) an ironNAI-50120701 S8v2 Page 23 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”).
[0098] In some embodiments, provided herein is a method of treating (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a siRNA described herein. In one aspect, provided herein is a siRNA for use in treating (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”) comprising administering to a subject in need thereof a therapeutically effective amount of a siRNA as described herein. In one aspect, a siRNA provided herein is used for the manufacture of a medicament for treatment of (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”).
[0099] In some embodiments of a method of treating Al, the subject has Al. In certain embodiments, the subject suffering from Al has a chronic infection, an autoimmune disease, chronic kidney disease, an anemia of the elderly, an advanced cancer, graft versus host disease, congestive heart failure, myelofibrosis, a myelodysplastic syndrome (MDS), irritable bowel syndrome, rheumatoid arthritis, sepsis, or chronic obstructive pulmonary disease.
[0100] Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis and chronic anemia. In at least a subset of patients, MDS is associated with dysregulated iron homeostasis and elevated hepcidin levels, which can contribute to iron-restricted erythropoiesis despite adequate or increased iron stores. Increased hepcidin expression in MDS has been linked to inflammatory signaling, altered bone marrow microenvironment, anddisease-associated cytokine production. Accordingly, therapeutic strategies that reduce hepcidin expression or activity may improve iron availability and support erythropoiesis in subjects with MDS.
[0101] In some embodiments of the methods provided above where a siRNA is administered to a subject, the siRNA is administered as a weight-based dose. A “weightbased dose” (e.g., a dose in mg / kg) where the amount of siRNA administered to a subject will depend on the subject’s weight. In some embodiments, the amount of siRNA administered is between 0.01 mg / kg to 45 mg / kg bodyweight of the subject.
[0102] In some embodiments of the methods provided above where a siRNA is administered to a subject, the siRNA is administered as a fixed dose. A “fixed dose” (e.g., a dose in mg) is an amount of siRNA administered irrespective of any subject-related factorsNAI-50120701 S8v2 Page 24 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT such as weight. In one embodiment, the amount of siRNA administered is between 0.5 mg to 900 mg.
[0103] The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease, disorder or condition, previous treatments, the general health, weight, and age of the subject, concomitant treatments, if any, and other individual characteristics of the subject to be treated.
[0104] In some embodiments of the methods provided above where a siRNA is administered to a subject, the method further comprises administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease, disorder or condition.
[0105] in one embodiment, provided herein is a siRNA for use in treating a disease, condition or disorder associated with elevated serum hepcidin comprising administerin to a subject in need thereof a therapeutically effective amount of a siRNA as described herein and a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease, disorder or condition.
[0106] in certain embodiments, the second therapeutic agent is iron supplementation; a Janus kinase (JAK) pathway inhibitor (e.g., a JAK inhibitor, such as ruxolitinib, fedratinib, or pacritinib or dual JAK / ALK2 inhibitor such as momelotinib); a BET inhibitor; a modulator of the transferrin receptor -2 (TFR2) pathway; a modulator of activin A receptor type 1 (ACVR1 / ALK2) signaling (e.g., an ACVR1 / ALK2 inhibitor such as zilurgisertib); a hemojuvelin antagonist (e.g., an anti-hemojuvelin antibody, an siRNA targeting hemojuvelin expression or small molecule inhibitor); a hepcidin antagonist (e.g., small molecule inhibitor); an erythroid maturation agent (e.g., a TGF-£ superfamily ligand trap, such as luspatercept); or another gene- or protein- modulating therapy other than a siRNA as disclosed herein.
[0107] In some embodiments, a HAMP-targeting siRNA as described herein is administered in combination with one or more additional therapeutic agents or nucleic acid molecules that modulate iron homeostasis, erythropoiesis, or signaling pathways that regulate HAMP expression. In certain embodiments, such combination therapies comprise (i) two or more distinct siRNA molecules targeting different genes involved in hepcidin regulation (“dual siRNA” therapy); (ii) an siRNA in combination with a small-molecule therapeutic agent; (iii) an siRNA in combination with a monoclonal antibody or antibody-based therapeutic; (iv) an siRNA in combination with an antisense oligonucleotide (ASO); or (v) a single molecular construct or composition comprising two or more inhibitory modalities. The components of such combination therapies may beNAI-50120701 S8v2 Page 25 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT administered separately, sequentially, or together, and may be formulated as separate compositions or as part of a single pharmaceutical composition.
[0108] In certain embodiments, a combination therapy as described herein comprises a HAMP-targeting siRNA and a second therapeutic agent that modulates a signaling pathway resulting in decreased HAMP expression. Non-limiting examples of such pathways include those involving hemojuvelin (HFE2 / HJV), transferrin receptor-2 (TFR2), activin A receptor type 1 (ACVR1 / ALK2), or erythroferrone-mediated signaling. The second therapeutic agent may act at the gene or protein level and may comprise, for example, a small-molecule inhibitor, antibody, nucleic acid-based inhibitor, or ligand trap, depending on therapeutic modality.EXAMPLESExample 1: Design of siRNAs Targeting HAMP
[0109] Design of siRNA was carried out to identify siRNAs targeting human HAMP with cross-reactivity for cynomolgus monkey and / or rhesus monkey using annotations from the NCBI RefSeq and Ensembl databases. All siRNA duplexes designed shared a minimum 17-merfull match (antisense positions 2-18) identity with human / cynomolgus or human / rhesus transcripts, and preferably a 19-mer full match (antisense positions 1-19) identity with human / cynomolgus or human / rhesus. Target sites with abundant single nucleotide polymorphisms (NCBI, dbSNP) were excluded. An alignment was created by performing a BLASTn search with human HAMP NCBI RefSeq transcript NM_021175.4 versus HAMP transcripts of human, cynomolgus and rhesus from NCBI RefSeq (release 225) and Ensembl (release 112) databases:a. Human: ENST00000222304.5 and ENST00000598398.5 b. Rhesus monkey: XM_015123671.2c. Cynomolgus monkey: ENSMFAT00000088784.1 and XM..005588836,4
[0110] Specificity was predicted based on full or partial complementarity of the siRNA antisense strand to off-target transcripts, classified by the number of mismatches (<4) within antisense positions 2-18. Seed-dependent microRNA-like off-target effects were predicted based on homology with known seed regions described in miRbase R22. Sequences were prioritized if they had a high predicted sequence specificity and low miRNA homology. A total of 49 siRNAs were selected for screening.
[0111] The siRNAs described herein were synthesized by methods known in the art. Refer to Table 1 for nomenclature on nucleotide monomers used in nucleic acid sequences described herein.NAI-50120701 S8v2 Page 26 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0112] Table 2 shows a total of 49 unique siRNA duplexes in 19 / 21 met format and 49 unique siRNA duplexes in 21 / 23mer format, totaling 98 siRNA duplexes, targeting the HAMP gene.TABLE 2NAI-50120701 S8v2 Page 27 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT TABLE 2NAI-50120701 S8v2 Page 28 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT TABLE 2
[0113] Table 3 shows the 98 unique siRNA duplexes targeting the HAMP gene, wherein siRNA antisense strand position 1 (AS1 ) = U, and the corresponding siRNA sense strand position 19 (SS19) = A. Thermodynamically preferred A / U base pairing at the 5’-end of the antisense strand is advantageous for strand orientation during RISC loading.TABLE 3NAI-50120701 S8v2 Page 29 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT TABLE 3NAI-50120701 S8v2 Page 30 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT TABLE 3
[0114] Table 4 shows 6 modification patterns for each sequence in Table 3, totaling 588 fully modified siRNA sequences. It is known that unmodified siRNAs are highly unstable and prone to exonuclease and endonuclease degradation. The combination of 2’- NAI-50120701 S8v2 Page 31 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT fluoro and 2’-O-methyl modifications allow for compound stabilization, exonuclease / endonuclease resistance, and preservation of activity. Phosphorothioates, in place of phosphodiester linkages, at positions on the sense and antisense strand provide additional stabilization against exonuclease degradation and contribute to cellular internalization, in Table 4 phosphorothioate linkages are denoted by “s.” Also in Table 4, a triantennary GalNAc is covalently attached to the 3’ end of the sense strands, which in these examples is the “L96” triantennary GalNAc. The triantennary GalNAc conjugate is recognized by the asialoglycoprotein receptor (ASGPR) expressed on the surface of hepatocytes and is responsible for the endocytosis mechanism of GalNAc-conjugated siRNAs. Further, a vinylphosphonate modification can be made to the 5’ end of the antisense strand, thus in the examples in Table 4 the nucleotide at the 5’end is 5’-(E)- vinylphosphonate-2’-O-methyluridine. A5’-vinylphosphonate modification is a phosphatase-resistant analog at the 5’-terminal of the antisense strand and is responsible for improving the RISC loading and potency of siRNAs.NAI-50120701 S8v2 Page 32 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 4Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTExample 2: In Vitro Screening of siRNA Activity in Hep3B cells
[0115] This example describes an assay using a cultured human cell line capable of expressing HAMP to evaluate the in vitro efficacy of siRNA provided herein in silencing HAMP.
[0116] Cell Culture and Transfections. Hep3B cells (ATCC, HB-8064) were cultured in Eagle's Minimum Essential Medium (Wisent, cat. no. 220-020-LL) supplemented with 10% FBS (Excell, cat. no. FSP500) at 37°C in an atmosphere containing 5% CO2. For siRNA transfections, cells were seeded at a density of 10,000 cells per well in 96-well plates. Lipofectamine RNAiMAX (Invitrogen, cat. no. 13778150) and siRNA were each diluted separately in Opti-MEM medium (ThermoFisher, cat. no. 31985062). Equal volumes of the diluted siRNA and RNAiMAX were combined in a 1:1 ratio and incubated for 10 minutes at room temperature. The resulting siRNA-li pid mixture was then added to cells to achieve final siRNA concentrations of 0.1 nM or 10 nM. Transfected cells were incubated with the siRNA-lipid mixture for 56 hours, followed by the addition of recombinant human BMP-6 (R& D, cat. no.507-BP-020) at a final concentration of 100 ng / mLfor 16 hours.
[0117] RT-qPCR. After 72 hours of siRNA treatment, cells were lysed and subjected to reverse transcription and real-time quantitative PCR (RT-qPCR) using the Cells-to-CT™ 1-Step TaqMan™ Kit (ThermoFisher, cat. no. A25603) according to the manufacturer’s protocol.
[0118] Relative fold change in mRNA expression was calculated using the AACt method, with RT-qPCR data normalized to mock-treated control cells.
[0119] Knockdown efficiency (“% HAMP KD”) was determined by quantifying the percentage reduction in HAMP expression in cells treated with HAMP-targeting siRNA relative to those treated with a non-targeting control siRNA.
[0120] Table 5 shows screening data for siRNAs at concentrations of 0.1 and 10 nM expressed as % HAMP KD.TABLE 5NAI-50120701 S8v2 Page 51 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT TABLE 5NAI-50120701 S8v2 Page 52 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 5
[0121] A scatter plot of the screening data for siRNAs at concentrations of 0.1 and 10 nM is shown in FIG. 1. Of the 49 siRNAs screened, 12 siRNAs achieved >85% knockdown at a dose of 10 nM (indicated as “selected” in FIG. 1), which were further characterized as explained below. The data point for duplex BD-80738 indicated by the uppermost data point on the right of the scatter plot (FIG. 1) shows that this siRNA alone achieved both >85% knockdown at a dose of 10 nM and >60% knockdown at a dose of 0.1 nM.Example 3: Dose-Response Characterization of siRNAs in Hep3B cells
[0122] This example provides dose-response characterization of exemplary HAMP-targeting siRNAs in a cultured human cell line capable of expressing HAMP.
[0123] Twelve siRNAs were selected as described in Example 2 for further dose¬ response characterization (30 nM to 0.11 pM) followingthe procedures described in Example 2. FIG.2 shows dose response data for the 12 exemplary siRNAs that achieved >85% knockdown of HAMP mRNAat 10 nM. The average IC50values and average maximum measured knockdown percentages for the 12 exemplary siRNAs are shown in Table 6.TABLE 6NAI-50120701 S8v2 Page 53 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTTABLE 6
[0124] As shown in Table 6, all 12 siRNAs assessed in this example had IC5o values below 0.5 nM indicating robust potency for inhibiting HAMP mRNA. Two siRNAs, BD-80738 and BD-80742 each had an average IC50of 0.06 nM and were further assessed as described below.
[0125] Hepcidin Protein Quantification. After 72 hours of siRNA treatment, cell culture supernatants were collected for hepcidin protein detection using the Human Hepcidin Quantikine ELISA Kit (R& D Systems, cat. no. DHP250), following the manufacturer’s instructions. A standard curve was generated using recombinant hepcidin standards provided in the kit. Duplicate readings for each standard and experimental sample were averaged, and the average zero standard optical density (O. D.) was subtracted. Hepcidin concentrations were interpolated from the standard curve, and values were multiplied by the sample dilution factor to determine the final concentration. The percentage of hepcidin secretion inhibition was determined by calculating the reduction in hepcidin levels in HAMP-targeting siRNA-treated samples relative to those treated with a non-targeting control siRNA.
[0126] Dose response knockdown of HAMP mRNA and hepcidin protein quantification for BD-80738 and BD-80742 are shown in FIG. 3. The IC5o values and maximum knockdown values for BD-80738 and BD-80742 are shown in Table 7.TABLE 7
[0127] Table 7 demonstrates that BD-80738 and BD-80742 each have robust potency for HAMP mRNA knockdown and corresponding hepcidin inhibition.Example 4: In vitro HAMP mRNA and Hepcidin knockdown in primary human hepatocytes
[0128] This example describes an assay using primary human hepatocytes expressing HAMP to evaluate the efficacy of siRNA provided herein in silencing HAMP. GalNAc-conjugated HAMP-targeting siRNAs were incubated with primary humanNAI-50120701 S8v2 Page 54 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCThepatocytes to allow free uptake (i.e., cell entry without transfection) of the test article into cells.
[0129] Primary Human Hepatocytes were sourced from commercial suppliers (e.g., Lonza). Primary Human Hepatocytes (PHH) (60,000 cells / well) were added to wells containing varying doses of each siRNA (1 uM to 0.59 pM) prepared in ultra-pure DNase / RNase-free water in technical triplicate on a single plate. The siRNA-treated hepatocytes were incubated at 37 °C and 5% CO2for 72 hours. siRNA activity was determined by measuring levels of target mRNA through qRT-PCR usingTaqMan primer / probe sets (ThermoFisher).
[0130] Relative fold change was calculated using the AACt method, with RT-qPCR data normalized to mock-treated control cells.
[0131] mRNA knockdown efficiency was determined by quantifying the percentage reduction in HAMP expression in cells treated with HAMP-targeting siRNA relative to those treated with a non-targeting control siRNA.
[0132] Hepcidin inhibition was performed for PHH studies as described in Example 3.
[0133] Knockdown of HAMP-targeting siRNAs in PHH is described in Table 8.Replicates of BD-80738 knockdown are shown in FIG.4.Table 8Example 5: Comparative Profiling of HAMP siRNAs
[0134] AD-45723 is a previously described HAMP-targeting siRNA, as reported for example in U. S. Patent No. 9,228,188, and is used herein as a reference compound for comparative evaluation with BD-80738.
[0135] in vitro profiling was performed in Hep3B cells stimulated with BMP6 according to Example 3. As shown in FIG.5, BD-80738 exhibited greater potency and HAMP knockdown efficiency than AD-45723.NAI-50120701 S8v2 Page 55 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0136] In vitro profiling was performed in primary human hepatocytes according to Example 4. As shown in FIG.6, BD-80738 achieved greater inhibition of HAMP mRNA and hepcidin relative to AD-45723.
[0137] Plasma stability was assessed for both BD-80738 and AD-45723. Pooled human blood was sourced from healthy volunteers with ethics approval. Plasma was obtained from a portion of whole blood by centrifugation (10,000g at 4 °C for 0 min).Plasma and phosphate buffer (pH 7.4) were pre-warmed in a 37 °C water bath for 10 min. Test compounds (2 pL of 100 pM) were added to 398 pL of pre-warmed plasma and mixed, providing a final siRNA concentration of 0.5 pM. A positive control compound (Patisiran; 2 pL of 200 pM) was added to 398 pL of plasma to provide a final concentration of 1 pM. For a negative control, test compound (2 pL of 100 pM) was added to 398 pL of pre-warmed phosphate buffer (pH 7.4). Aliquots (50 pL) were prepared for each time point and incubated at 37 °C. At 0, 1, 2, 6, and 24 h, the corresponding aliquots were transferred to -80 °C. After collection of the final time point, samples were thawed and processed for LC-MS / MS analysis using an internal standard. Briefly, an internal standard solution (Mipomersen in MeOH: H2O (1:1)) was added, followed by ammonium hydroxide, mixing, and centrifugation. Samples were then subjected to extraction / cleanup using a DNA extraction reagent quench solution and phase separation with dichloromethane. The aqueous supernatant was collected, concentrated under nitrogen at elevated temperature, reconstituted in mobile phase (95% mobile phase A / 5% mobile phase B), mixed, centrifuged, and transferred to plates for LC-MS / MS analysis.
[0138] Peak areas were determined from extracted ion chromatograms, and percent parent remaining at each time point was calculated as: Remainingt,min(%) = (Peak Area Ratio,min / Peak Area Ratio0niin)x100, where Peak Area Ratiotminrepresents the peak area ratio of test compound to control compound at the indicated time point. The natural logarithm of averaged percent parent remaining was plotted versus incubation time, and the slope was determined by linear regression. The in vitro half-life (t1 / 2) was calculated from the rate constant k (k = -slope) according to t1 / 2= 0.693 / k.
[0139] As shown in FIG.7, BD-80738 exhibited a higher remaining percentage of antisense strand over time compared to AD-45723, indicating increased plasma stability of BD-80738 under the assay conditions.Example 6: In vitro knockdown in primary cyno hepatocytes
[0140] This example describes an assay using primary cynomolgus hepatocytes (PCH) expressing HAMP to evaluate the efficacy of siRNA provided herein in silencing HAMP expression. GalNAc conjugated HAMP-targeting siRNAs were incubated with PCH to allow free uptake of siRNA into cells with transfection.NAI-50120701 S8v2 Page 56 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT
[0141] The procedure was performed as described in Example 4. Primary cynomolgus hepatocytes were obtained from a commercial supplier.
[0142] Knockdown of HAMP mRNA in PCH following treatment with HAMP-target siRNA is summarized in Table 9. FIG. 8 shows dose-dependent knockdown of HAMP mRNA in primary cynomolgus hepatocytes by BD-80738 across three independent replicates (n1 to n3).Table 9Example 7: In Vivo Efficacy in Animal Model
[0143] The in vivo efficacy of the siRNA as provided herein can be tested in a rodent model of anemia associated with elevated hepcidin levels. Rodent models are described in, e.g., Asadur Rahman et al., PLoS ONE 13(2):e0192531 (2018), Arie Kim et al., Blood, vol.123, pages 1129-1136 (2014) and Seth Rivers et al., Blood, vol. 105, pages 1797-1802 (2005). The siRNA can be delivered, for example, as a subcutaneous injection in phosphate-buffered saline, and the serum concentration of hepcidin is measured and / or the expression level of HAMP quantitated.Example 8: Inhibition of HAMP in Humans
[0144] A human subject is treated with a siRNA as provided herein to inhibit expression of the HAMP gene to treat a condition, e.g., an anemia of inflammation, in some instances, one or additional therapy is administered to the subject, such as, for instance, iron supplementation or a hepcidin antagonist (e.g., an anti-hepcidin antibody or small molecule inhibitor, BMP / SMAD pathway inhibitor, or JAK inhibitor).
[0145] A subject in need of treatment is selected or identified. The identification of the subject can occur in a clinical setting. On the first day of treatment, a suitable first dose of a siRNA as provided herein is administered to the subject. The siRNA is formulated as described herein. Followingthe first dose, e.g., 7 days, 14 days, and 21 days, the subject’s condition is evaluated and relevant criteria measured, including, for instance, measurement of hepcidin levels and / or HAMP expression in the subject. The number and dose amounts are adjusted according to the subject’s needs.NAI-50120701 S8v2 Page 57 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTEQUIVALENTS AND SCOPE
[0146] Although for purposes of clarity of understanding the foregoing embodiments are described in some detail by way of illustration and example, it will be readily apparent to those skilled in the art that certain changes and modifications may made thereto without departing from the spirit or scope of the appended claims. Only such limitations as appear in the appended claims should be placed on any claimed invention.
[0147] All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each publication, patent, or patent application were specifically and individually indicated to be incorporated by reference.NAI-50120701 S8v2 Page 58 of 68
Claims
1. Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTCLAIMS1. A small interfering ribonucleic acid (siRNA), comprising a sense strand and an antisense strand forming a double stranded region, wherein the sense strand and antisense are a duplex selected from the group consisting of duplexes listed in TABLE 4 of the specification,wherein a, c, g, and u are 2’-O-methyladenosine-3’-phosphate, 2’-O- methylcytidine-3’-phosphate, 2’-O-methylguanosine-3’-phosphate, and 2’-O- methyluridine-3’-phosphate, respectively;as, cs, gs, and us are 2’-O-methyladenosine-3’-phosophorothioate, 2’-O- methylcytidine-3’-phosphorothioate, 2’-O-methylguanosine-3’-phosphorothioate, and 2’-O-methyluridine-3’-phosphorothioate, respectively;Af, Cf, Gf, and Uf are 2’-fluoroadenosine-3’-phosphate, 2’-fluorocytidine-3’- phosphate, 2’-fluoroguanosine-3’-phosphate, and 2'-fluorouridine-3’-phosphate, respectively; andAfs, Cfs, Gfs, and Ufs are 2’-fluoroadenosine-3’-phosphorothioate, 2’- fluorocytidine-3’-phosphorothioate, 2’-fluoroguanosine-3’-phosphorothioate, and 2’-fluorouridine-3’-phosphorothioate, respectively; andwherein a triantennary GalNAc is covalently attached to the 3’ end of the sense strand and the nucleotide at the 5’ end of the antisense strand comprises a 5’vinylphosphonate.
2. A small interfering ribonucleic acid (siRNA), comprising a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a modified nucleotide sequence selected from the group consisting of:5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648),5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649), 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650),5’-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ),5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732),NAI-50120701 S8v2 Page 59 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733),5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734),5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735), 5'-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836),5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837),5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838), and 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839);whereina is 2’-O-methyladenosine-3’-phosphate,as is 2’-O-methyladenosine-3’-phosophorothioate,Af is 2’-fluoroadenosine-3’-phosphate,Afs is 2’-fluoroadenosine-3’-phosphorothioate,c is 2’-O-methylcytidine-3’-phosphate,cs is 2’-0-methylcytidine-3’-phosphorothioate,Of is 2’-fluorocytidine-3’-phosphate,Cfs is 2’-fluorocytidine-3’-phosphorothioate,g is 2’-O-methylguanosine-3’-phosphate,gs is 2’-0-methylguanosine-3’-phosphorothioate,Gf is 2’-fluoroguanosine-3’-phosphate,u is 2’-O-methyluridine-3’-phosphate,us is 2’-O-methyluridine-3’-phosphorothioate,Uf is 2’-fluorouridine-3’-phosphate,Ufs is 2’-fluorouridine-3’-phosphorothioate; andwherein the nucleotide at the 5’ end of the antisense strand comprises a 5’.vinylphosphonate.
3. The siRNA of claim 2, wherein the sense strand comprises a modified nucleotide sequence selected from the group consisting of:5’-asascagaCfgGfGfAfcaacUfUfgcaa-3’ (SEQ ID NO:354),NAI-50120701 S8v2 Page 60 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT5’-asascagaCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355),5’-asascagaCfgGfGfAfcaacuugcaa-3' (SEQ ID NO:356),5’-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357),5'-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358),5’-asascaGfaCfGfGfgacaAfcuUfga-3’ (SEQ ID NO:359),5’-csusgcllfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480),5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’ (SEQ ID NO:481 ),5’-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482),5’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483),5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484),5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485),5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636),5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637),5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638),5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639),5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NO:640), and 5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641);whereina is 2’-O-methyladenosine-3’-phosphate,as is 2’-0-methyladenosine-3’-phosophorothioate,Af is 2’-fluoroadenosine-3’-phosphate,c is 2’-0-methylcytidine-3’-phosphate,cs is 2’-O-methylcytidine-3’-phosphorothioate,Cf is 2’-fl.uorocytidine-3’-phosphate,g is 2’-O-methylguanosine-3’-phosphate,gs is 2’-0-methylguanosine-3’-phosphorothioate,Gf is 2’-fluoroguanosine-3’-phosphate,u is 2’-O-methyluridine-3’-phosphate,us is 2’-O-methyluridine-3’-phosphorothioate, andNAI-50120701 S8v2 Page 61 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCTUf is 2’-fluorouridine-3’-phosphate;wherein a triantennary GalNAc is covalently attached to the 3’ end of the sense strand.
4. The siRNA of claim 3, wherein the triantennary GalNAc is L96, wherein the L96 is5. The siRNA of any one of claims 2 to 4, wherein the antisense strand and sense strand comprise a pair of modified nucleotides sequences selected from the group consisting of:(a) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and5’-asascagaCfgGfGfAfcaacllfUfgcaa-3’ (SEQ ID NO:354);(b) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and5’-asascagaCfgGfGfAfcaacUfUfgcaa-3’ (SEQ ID NO:354);(c) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and5’-asascagaCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355);(d) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and5’-asasca aCfgGfGfAfcaacUfugCfaa-3’ (SEQ ID NO: 355);(e) 5’-usUfsgcaAfguuguccCfgUfcuguusgsu-3’ (SEQ ID NO:648) and5’-asascagaCfgGfGfAfcaacuugcaa-3’ (SEQ ID NO:356);(f) 5’-usUfsgcaAfgUfUfguccCfgUfcuguusgsu-3’ (SEQ ID NO:649) and5’-asascagaCfgGfGfAfcaacuugcaa-3’ (SEQ ID NO:356);NAI-50120701 S8v2 Page 62 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT(g) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650) and5’-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357);(h) 5’-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) and5'-asascaGfaCfGfGfgacaacuuga-3’ (SEQ ID NO:357);(i) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650) and5’-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358);(j) 5’-usCfsaagUfuGfUfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) and5’-asascaGfaCfGfGfgacaAfCfuuga-3’ (SEQ ID NO:358);(k) 5’-usCfsaagUfugucccgUfcUfguusgsu-3’ (SEQ ID NO:650) and5’-asascaGfaCfGfGfgacaAfcuUfga-3’ (SEQ ID NO:359);(l) 5’-usCfsaagUfuGf UfcccgUfcUfguusgsu-3’ (SEQ ID NO:651 ) and5’-asascaGfaCfGfGfgacaAfcuUfga-3’ (SEQ ID NO:359);(m) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) and5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480);(n) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480);(o) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) and5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’ (SEQ ID NO:481 );(p) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and5’-csusgcUfgUfCfAfucgaUfcaAfaa-3’ (SEQ ID NO:481);(q) 5’-usUfsuugAfucgaugaCfaGfcagscsc-3’ (SEQ ID NO:732) and5'-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482);(r) 5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and5’-csusgcUfgUfCfAfucgaUfCfaaaa-3’ (SEQ ID NO:482);(s) 5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) and5’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483);(t) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and5’-csusgcugUfcAfUfCfgaucaaagua-3’ (SEQ ID NO:483);(u) 5’-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) andNAI-50120701 S8v2 Page 63 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484);(v) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and5’-csusgcugUfcAfUfCfgaucAfaaGfua-3’ (SEQ ID NO:484);(w) 5'-usAfscuuUfgaucgauGfaCfagcagscsc-3’ (SEQ ID NO:734) and5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485);(x) 5’-usAfscuuUfgAfUfcgauGfaCfagcagscsc-3’ (SEQ ID NO:735) and5’-csusgcugUfcAfUfCfgaucAfAfagua-3’ (SEQ ID NO:485);(y) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(z) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(aa) 5’-usAfscacUfuugaucgAfuGfacasgsc-3' (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(bb) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(cc) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(dd) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(ee) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(ff) 5'-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(gg) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and5’-usgsucauCfgAfUfCfaaagUfguGfga-3’(SEQ ID NO:640);(hh) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and5’-usgsucauCfgAfUfCfaaagUfguGfga-3’(SEQ ID NO:640);(ii) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641); andNAI-50120701 S8v2 Page 64 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT(jj) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ).
6. The siRNA of any one of claims 2 to 5, wherein the antisense strand and sense strand comprise a pair of modified nucleotides sequences selected from the group consisting of:(y) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(z) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and5’-usgsucAfuCfGfAfucaaAfGfugua-3’ (SEQ ID NO:636);(aa) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(bb) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and5’-usgsucAfuCfGfAfucaaAfguGfua-3’ (SEQ ID NO:637);(cc) 5’-usAfscacUfuugaucgAfuGfacasgsc-3’ (SEQ ID NO:836) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(dd) 5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638);(ee) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and5’-usgsucauCfgAfUfCfaaagUfGfugga-3’ (SEQ ID NO:639);(ff) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and5'-usgsucauCfgAfUfCfaaagUfGfugga-3’(SEQ ID NO:639);(gg) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and5’-usgsucauCfgAfUfCfaaagUfguGfga-3’(SEQ ID NO:640);(hh) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) and5’-usgsucauCfgAfUfCfaaagUfguGfga-3’ (SEQ ID NO:640);(ii) 5’-usCfscacAfcuuugauCfgAfugacasgsc-3’ (SEQ ID NO:838) and5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641); and(jj) 5’-usCfscacAfcUfUfugauCfgAfugacasgsc-3’ (SEQ ID NO:839) andNAI-50120701 S8v2 Page 65 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT5’-usgsucauCfgAfUfCfaaagugugga-3’ (SEQ ID NO:641 ).
7. The siRNA of any one of claims 1 to 6, wherein the antisense strand and sense strand comprise:5’-usAfscacUfuUfGfaucgAfuGfacasgsc-3’ (SEQ ID NO:837) and5’-usgsucAfuCfGfAfucaaagugua-3’ (SEQ ID NO:638).
8. The siRNA of any one of claims 1 to 5, wherein the antisense strand and sense strand comprise:5’-usUfsuugAfuCfGfaugaCfaGfcagscsc-3’ (SEQ ID NO:733) and5’-csusgcUfgUfCfAfucgaucaaaa-3’ (SEQ ID NO:480).
9. A cell comprisingthe siRNA of any one of claims 1 to 8.
10. A pharmaceutical composition comprisingthe siRNA of anyone of claims 1 to 8 and a pharmaceutically acceptable excipient or carrier.
11. The pharmaceutical composition of claim 10 further comprising a lipid nanoparticle formulation.
12. A method of inhibiting HAMP expression in a cell, the method comprising:(a) introducingthe siRNA of any one of claims 1 to 8 into the cell and(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of HAMP mRNA, thereby inhibiting expression of HAMP in the cell.
13. A method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of the siRNA of any one of claims 1 to 8.NAI-50120701 S8v2 Page 66 of 68Attorney Docket No.: 14874-007-228 Ref. No.: BRB0025PCT14. A method of treating a disease, condition or disorder associated with elevated serum hepcidin, the method comprising administerin to a subject in need of such treatment a therapeutically effective amount of the siRNA of any one of claims 1 to 8.
15. The method of claim 14, wherein the disease, condition or disorder associated with elevated serum hepcidin is (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”).
16. A method of boosting erythropoiesis in a subject having an anemia, the method comprising administerin to the subject a therapeutically effective amount of the siRNA of any one of claims 1 to 8.
17. A method of treating (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”) in a subject in need thereof, the method comprising administeringto the subject a therapeutically effective amount of the siRNA of any one of claims 1 to 8.
18. The method of claim 17, wherein the subject has Al.
19. The method of claim 18, wherein the subject has a chronic infection, an autoimmune disease, chronic kidney disease, an anemia of the elderly, an advanced cancer, graft versus host disease, congestive heart failure, myelofibrosis, a myelodysplastic syndrome (MDS), irritable bowel syndrome, rheumatoid arthritis, sepsis, or chronic obstructive pulmonary disease.
20. The method of any one of claims 12 to 19, wherein the method further comprises administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease, disorder or condition.NAI-50120701 S8v2 Page 67 of 68
